Belmore Neidrauer is pleased to announce that the firm has been shortlisted for Firm of the Year – Patent Disputes (Canada) at the upcoming Managing IP Awards 2025.
It is with heartfelt sadness we share the passing of Belmore Neidrauer’s senior Partner and our dear friend Peter Wilcox.
Peter was a fierce advocate for his clients, a deeply respected leader and force in the IP community, and an incredible mentor to our team and to many others in the profession.
Belmore Neidrauer is pleased to be recognized in the inaugural edition of Best Law Firms™ - Canada. The listings highlight leading law firms for their exceptional performance across regions, practice areas and on a national scale.
The 2025 edition of Best Lawyers in Canada™ has recognized partners Peter Wilcox, Marian Wolanski and Stephanie Anderson as being amongst the leading lawyers in Canada (Intellectual Property Law).
Belmore Neidrauer secured another victory in the Federal Court of Appeal for our client Janssen relating to the validity of Janssen’s patent covering INVEGA SUSTENNA®
We successfully represented Janssen on another appeal relating to infringement of Janssen’s patent covering INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia.
We successfully represented Janssen in the Federal Court of Appeal on this appeal relating to infringement of the patent covering Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia.
Belmore Neidrauer has successfully represented Janssen on another appeal, resulting in a decision overturning the Federal Court’s denial of summary judgment.
We successfully represented Janssen on Teva’s appeal and Janssen’s cross-appeal in a significant decision relating to the law of inducing patent infringement in Canada. The decision relates to Janssen’s patent covering INVEGA SUSTENNA® (paliperidone ...
We successfully represented Janssen in a motion to appeal an order of the Associate Judge which declined, based on relevance, to compel Apotex to answer certain discovery questions related to its ability to supply its generic abiraterone acetate prod...
We successfully represented Janssen in a motion to Amend its Statement of Defence in this PMNOC section 8 damages action. The Court agreed that Janssen was allowed to amend its Statement of Defence to raise issues as to Apotex’s ability to supply the...
We successfully represented Janssen in this motion brought by Dr. Reddy’s in the context of a PMNOC section 8 damages action. Dr. Reddy’s was seeking to have a question of law determined before trial. The question of law related to whether Janssen co...
We successfully represented Janssen in a motion brought by the appellant (Pharmascience) to settle the contents of the appeal book in the context of an appeal from the judgment of the Federal Court in Janssen Inc. v. Pharmascience Inc., 2022 FC 1218 ...
This was an application to add an inventor to two patents owned by Alexion Pharmaceuticals. The patents relate to Alexion’s blockbuster drug SOLIRIS. The application was granted, ensuring that the correct inventors are named on the patents relating t...
We successfully represented Janssen on these motions seeking non-party discovery in three PMNOC section 8 actions.Each of Apotex, Dr. Reddy’s and Pharmascience resisted, on numerous grounds, non-party discovery for use in these section 8 actions. The...
We successfully represented Janssen in defending the validity of the patent relating to Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product used to treat schizophrenia.
We successfully represented Janssen in this summary trial in the Federal Court on infringement issues against Apotex in respect of Janssen’s patent covering its important INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product used t...
We successfully represented Janssen in this summary trial in the Federal Court on infringement issues against Pharmascience in respect of Janssen’s patent covering its important INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product...
We represented Janssen and BTG in these patent infringement actions relating to Janssen’s prostate cancer product ZYTIGA®(abiraterone acetate). We were successful in proving inducing infringement and in resisting the defendants’ attacks based on lack...
We successfully represented Pfizer on this appeal related to a mechanical device patent and Pfizer’s epinephrine auto injector product EpiPen®. The Federal Court of Appeal upheld the trial judge’s decision on claim construction, anticipation, obvious...
We successfully represented Janssen on this appeal. The Federal Court of Appeal upheld the trial judge’s decision that the patent was valid and infringed. On validity, the Court clarified the nature of evidence that can be used to establish demonstra...
We successfully represented Elea on this appeal. J.R Simplot, the defendant in a patent infringement action brought by McCain, had issued a third party claim against Elea, alleging that Elea was responsible for any damages that Simplot may be require...
We successfully represented Pfizer in this patent infringement action. Seedlings – a non-practicing entity – alleged that Pfizer’s EpiPen infringed a Seedlings patent. Seedlings was seeking all of the profits earned by Pfizer on EpiPen sales since 20...